*EMBARGOED All research presented at the 2022 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 23, 2022, at 12:00 pm EDT.
Oral 11 – Dupilumab Improves Clinical, Symptomatic, Histologic, and Endoscopic Aspects of EoE up to 24 Weeks: Pooled Results From Parts A and B of Phase 3 LIBERTY-EoE-TREET
Monday, October 24, 2022 | 2:15 PM – 2:25 PM ET | Location: Hall C2
Author Insight from Evan S. Dellon, MD, MPH, FACG, University of North Carolina School of Medicine
What’s new here and important for clinicians?
Dupilumab is now the only medication FDA-approved to treat EoE in the US. The findings here are that the pooled efficacy and safety data for parts A and B of the phase 3 trial are consistent with the results of the individual parts of the study that were previously reported, and which led to the drug being approved for EoE. Of note, the approved dose is 300mg weekly as a subcutaneous injection.
What do patients need to know?
If they have EoE, dupilumab might be an option for treatment. However, it’s important to realize that in the phase 3 study, all patients were PPI non-responders, most had been treated with topical steroids (and many were not responsive), and many had prior esophageal dilation. We don’t have a lot of data in more mild EoE patients, and insurances are currently requiring a series of authorization before patients might be able to get this medication. It’s best to talk to their doctor about whether the medication is a good fit or not.
Read the Abstract
Evan S. Dellon, MD, MPH, FACG, University of North Carolina School of Medicine
edellon [at] med.unc.edu
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.